<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04206033</url>
  </required_header>
  <id_info>
    <org_study_id>RC19_0446</org_study_id>
    <nct_id>NCT04206033</nct_id>
  </id_info>
  <brief_title>Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins</brief_title>
  <acronym>BOHEM</acronym>
  <official_title>Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose, as part of the study, to carry out for each patient:

        -  An analysis of monocytic populations by flow cytometry (CD14, CD16, CD45, CD68, CD115,
           CCR2, CX3CR1, CD163 and CD206).

        -  A population assessment of Myeloid-Derived Suppressor Cells (MDSC).

        -  Assays of cytokines and chemokines involved in inflammation by multiplex analyzes: Il-1
           (α and β), Il-4, Il-6, Il-10, Il-13, TNF- α, TGF- β, CRP , leptin, IFN- β.

        -  Specialized dosages of proteins involved in bone metabolism. RANKL, osteoprotegerin,
           M-CSF, TRAPCP5.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 17, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To study the monocytic populations possibly involved in bone metabolism in hemophiliac patients.</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of the inflammatory profile of patients by protein assays</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Find a correlation between the main objective and the measurement of bone density</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of biochemical parameters involved in bone metabolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Find a correlation between the main objective and the measurement of bone density</measure>
    <time_frame>1 year</time_frame>
    <description>Non-invasive bone mineral density measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Look for a correlation between the main objective and physical activity</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of physical activity by self-questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Look for a correlation between the main objective and the inflammatory profile in hemophiliac patients.</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluation of the inflammatory profile of patients by protein assays</description>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hemophilia</condition>
  <condition>Osteopenia</condition>
  <condition>Arthropathy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>Observational study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        It will include adult male patients with hemophilia A or B, severe, moderate or minor.

        In addition, the investigators will include patients with Hemophilia A with an inhibitor.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patients followed at the hemophilia treatment reference center,

          -  Presenting the diagnosis of severe, moderate or minor Hemophilia A / B,

          -  Having a social security system,

          -  Obtaining the oral non-objection collection from the patient after information.

        Exclusion Criteria:

          -  Minor patients, under guardianship or curatorship.

          -  Causes of secondary osteoporosis:

               -  Systemic corticosteroid therapy in progress (≥ 3 consecutive months, at a dosage
                  ≥ 7.5 mg / d of prednisone equivalent).

               -  other treatment or condition responsible for osteoporosis: prolonged or medicated
                  hypogonadism, untreated active hyperthyroidism, hypercorticism, primary
                  hyperparathyroidism.

          -  Treatment with biphosphonates, biotherapies or hormone therapy in the treatment of
             prostate cancer.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marc Fouassier, MD</last_name>
    <phone>0240084049</phone>
    <email>marc.fouassier@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Fouassier, MD</last_name>
      <phone>0240084049</phone>
      <email>marc.fouassier@chu-nantes.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

